Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Pathogenesis, Diagnostics and Prognostics in Head and Neck Cancer"
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (7 March 2023) | Viewed by 2592
Special Issue Editors
Interests: tumor immunology; tumor–host interaction; molecular pathogenesis; microcirculation; radiomics; machine learning; salivary gland disorders
Interests: cancer diagnostics; cancer stem cells; radiomics; machine learning; regenerative medicine; cancer prognosticators; medical education
Special Issue Information
Head and neck cancer is among the most prevalent cancers worldwide, and head and neck squamous cell carcinoma (HNSCC) is the histopathology most commonly found.
Based on common risk factors, such as alcohol and tobacco use on the one hand and human papilloma virus (HPV) on the other hand, differences in its pathogenesis and prognosis are known.
Although HPV-associated HNSCC has supposedly better therapy outcomes, improvements in HNSCC prognosis are still marginal.
Therefore, new insights into the tumor biology and pathogenesis of HNSCC are needed. Promising fields of HNSCC research include the tumor microenvironment with, e.g., immune cell infiltrates and cancer-associated fibroblasts. Moreover, cancer stem cells, exosomes and circulating tumor cells are associated with disease progression.
Novel markers, but also techniques such as proteomics or radiomics and computational advances, e.g., machine or deep learning algorithms, guide new ways to improve diagnostics and prognostication in HNSCC, and may lead to treatment deintensification as well as new treatment options.
Therefore, we are looking for manuscripts covering new insights in the pathogenesis, diagnostics and prognostics of HNSCC. We welcome experimental, translational and clinical research articles, as well as review articles.
Prof. Dr. Christoph A. Reichel
Dr. Kariem Sharaf
Dr. Axel Lechner
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- molecular pathogenesis
- tumor microenvironment
- tumor biology
- tumor immunology
- targeted therapy
- treatment deintensification
- neoadjuvant therapy